The National Health
Research Ethics Committee, Nigeria, has approved the use of an experimental
Ebola drug, Zmapp, for treatment of patients infected with the virus. The
committee, which composed research scientists, is a national body under the
Federal Ministry of Health.
The endorsement is
contained in a statement issued to newsmen by Prof. Clement Adebamowo,
Chairman of the committee on Wednesday in Abuja. Continue...
The decision by the
committee is coming on the heels of Tuesday’s approval by the World Health
Organisation (WHO) on the use of Zmapp for treatment of Ebola patients.
“It is ethical to use
these treatments in the current situation without first submitting an
application to National, State or Institutional Health Research Ethics
Committee for prior review and approval.
“In addition, the
Committee waives the current requirement that international shipment of any
biological samples out of Nigeria should be preceded by the establishment of a
Materials Transfer Agreement.
“This waiver is to
promote rapid international response to this global emergency,’’ the statement
said.
In the statement, the
Nigerian National Code for Health Research Ethics emphasised that all
innovative and non-validated treatments should be carefully and adequately
documented.